023910.KQ
Daihan Pharmaceutical Co.,Ltd.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 27,250.00
+1.49%Year over year
Reported trailing growth
- Revenue
- +4.3%
- EBITDA
- -11.8%
- EBIT
- -17.5%
- EPS
- -12.1%
- Free cash flow
- +46.4%
- Operating cash flow
- +8.5%
Forward estimates
Based on analyst estimates
- Revenue
- -48.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.2%
- EBITDA
- -2.2%
- EBIT
- -1.8%
- Net income
- +3.5%
- EPS
- +4.1%
- Free cash flow
- -71.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026